Involved-field radiotherapy is effective for patients 70 years old or more with early stage non-small cell lung cancer

Yu, Hui; Liu, Yun Fang; Yu, Jin; Liu, Jie; Zhao, Yong; Hou, Ming

doi:10.1016/j.radonc.2008.01.008

Cited by 27 publications

(21 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yu et al treated 80 patients 70 years or more with early stage (I / II) with IF-RT using intensity modulated radiation therapy (IMRT). Although 29 patients (36.7%) with ENF were identified, they concluded IF-RT using IMRT did not cause a significant amount of lymph node regions and improved outcomes in elderly patients 12) . Matsuura et al reported 10 patients with locally advanced NSCLC (9 patients in stage IIIB) were treated with hypofractionated IF-RT (median dose 65 Gy / 26 fr), and no ENF was encountered with good feasibility 18) .…”

Section: The Evidence Of If-rt -Is Eni Needed?mentioning

confidence: 98%

See 1 more Smart Citation

Involved-Field Radiation Therapy (IF-RT) for Non-Small Cell Lung Cancer (NSCLC)

Kimura¹

2012

Modern Practices in Radiation Therapy

View full text Add to dashboard Cite

Section: The Evidence Of If-rt -Is Eni Needed?mentioning

confidence: 98%

“…The argument against the use of ENI may be summarized as follows 6,7) . 1) Failure is uncommon in nodal regions that are neither clinically involved nor specially targeted from many reports [8][9][10][11][12] .…”

Section: The Evidence Of If-rt -Is Eni Needed?mentioning

confidence: 99%

Involved-Field Radiation Therapy (IF-RT) for Non-Small Cell Lung Cancer (NSCLC)

Kimura¹

2012

Modern Practices in Radiation Therapy

View full text Add to dashboard Cite

“…Owing to the highly inhomogeneous distributions accepted with SABR, target dose homogeneity in the PTV should be within 20% 14,17,39,40 and the target reference point dose should be defined at the isocentre of the beam. 39,40 PTV dosimetric criteria In order to critically assess the clinical acceptability of a plan, the conformity of the PTV coverage will be judged as given in the tables below, incorporating constraints used in the ROSEL study (Table 5).…”

Section: Prescription Pointmentioning

confidence: 99%

A forward planned treatment planning technique for non-small-cell lung cancer stereotactic ablative body radiotherapy based on a systematic review of literature

Marchant¹,

Macwan

2015

J Radiother Pract

View full text Add to dashboard Cite

This document is the author deposited version. You are advised to consult the publisher's version if you wish to cite from it. Published versionMARCHANT, Anne C. and MACWAN, Sheela (2015). A forward planned treatment planning technique for non small cell lung cancer stereotactic ablative body radiotherapy. Based on a Systematic Review of Literature. Journal of Radiotherapy in Practice, 14 (04), 425-437. Copyright and re-use policy AbstractPurpose and Method: A systematic literature review of six computerised databases was undertaken in order to review and summarise a forward planned lung stereotactic ablative body radiotherapy (SABR) treatment planning (TP) technique as a starting point for clinical implementation in the author's department based on current empirical research. The data were abstracted and content analysed to synthesise the findings based upon a SIGN quality checklist tool.Findings: A four-dimensional computed tomography scan should be performed upon which the internal target volume and organs at risk (OAR) are drawn. A set-up margin of 5 mm is applied to account for inter-fraction motion. The field arrangement consists of a combination of 7-13 coplanar and non-coplanar beams all evenly spaced. Beam modifiers are used to assist in the homogeneity of the beam, although a 20% planning target volume dose homogeneity is acceptable. The recommended fractionations by the UK SABR Consortium are 54 Gy in 3fractions(standard),55-60 Gy in 5 fractions (conservative) and 50-60 Gy in 8-10 fractions (very conservative). Conformity indices for both the target volume and OAR will be used to assess the planned distribution.Conclusion: An overview of a clinically acceptable forward planned lung SABR TP technique based on current literature as a starting point, with a view to inverse planning with support from the UK SABR Consortium mentoring scheme.

show abstract

“…n Stage Median age (range) Radiotherapy dose/fractionation Survival Gd 3+ acute oesophagitis/pneumonitis Gauden and Tripcony [18] 162 I 50 Gy (2.5 Gy per fraction) minimum tumour dose 34% at 5 years Not recorded Furuta et al [15] 32 I-II 79 (75)(76)(77)(78)(79)(80)(81)(82)(83)(84)(85)(86) >60 Gy (2.0 Gy per fraction) 40% at 2 years 0 Bonfili et al [14] 36 I-II 77 60 Gy (3.0 Gy per fraction) 55.6% at 2 years 0 San Jose et al [12] 33 I-II 75 Median 70 Gy (2.0 Gy per fraction) 50% at 3 years 6% Yu et al [27] 80 I-II 76 (70)(71)(72)(73)(74)(75)(76)(77)(78)(79)(80)(81)(82)(83)(84) 66.6 Gy (1.8 Gy per fraction) 55.7% at 2 years 5.1% Pergolizzi et al [26] 40 IIIa 77 (75)(76)(77)(78)(79)(80)(81)(82)(83) Median 60 Gy (2.0 Gy per fraction) 18% at 3 years 5% Lonardi et al [11...…”

Section: Referencementioning

confidence: 99%